Subscribe: Agilent News - All
http://www.agilent.com/about/newsroom/rss/agilent_news.xml
Preview: Agilent News - All

Agilent Newsroom



Agilent press releases, feature stories, business briefs and more.



Published: Mon, 19 Jun 2017 08:00:00 PDT

Copyright: Copyright (c) 2017 Agilent Technologies, Inc.
 






Agilent Technologies Announces Expanded Use of Cancer Diagnostic in Europe

Fri, 16 Jun 2017 02:00:00 PDT

PD-L1 IHC 28-8 pharmDx Will Give More Insight to Which Patients with Urothelial Cancer are Most Likely to Benefit from Opdivo (nivolumab)



Agilent Technologies Global Lab Manager Survey Reveals Key Insights

Wed, 07 Jun 2017 08:00:00 PDT

Understanding of Lab Manager Challenges to Provide Trusted Answers is Pivotal to Ongoing Customer Satisfaction



Agilent Technologies Introduces New GC/Q-TOF System Enabling Greater Exploration of Unknown Chemical Samples

Tue, 06 Jun 2017 08:00:00 PDT

Third-Generation Instrument Delivers Enhanced Analytical Performance and Unique Capabilities



Agilent Technologies Announces Revolutionary Triple Quadrupole Mass Spectrometer

Mon, 05 Jun 2017 10:30:00 PDT

New LC/MS Triple Quadrupole is 70% Smaller Footprint but Equivalent Performance to Larger Instruments



Agilent Technologies and Agendia Sign Agreement on Molecular Cancer Diagnostics

Fri, 02 Jun 2017 08:00:00 PDT

Agreement Accelerates the Development of Tests to Help Assess Risk of Disease Recurrence in Women with Early-Stage Breast Cancer



Agilent Technologies Inspires at ASMS 2017 with Innovative Technology Solutions

Thu, 01 Jun 2017 08:00:00 PDT

New Solutions for Mass Spectrometry Further Enhance Lab Efficiency and Productivity



Agilent Technologies Reports Second-Quarter Fiscal Year 2017 Financial Results

Mon, 22 May 2017 13:00:00 PDT

Strong Second Quarter, Raises Full-Year Guidance









Agilent Technologies Announces Expanded Use for PD-L1 IHC 28-8 pharmDx Diagnostic in Europe

Mon, 15 May 2017 08:00:00 PDT

Approved for Use in Europe to Identify Head and Neck Cancer Patients Most Likely to Benefit from Opdivo (nivolumab) Therapy